Nuclear Factor Erythroid 2 Related Factor 2 drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Central Nervous System, Oncology, and Ophthalmology which include the indications Multiple Sclerosis, Unspecified Neurologic Disorders, Breast Cancer, Ovarian Cancer, Age Related Macular Degeneration, and Retinal Degeneration. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics development with respective active and dormant or discontinued products.

The Nuclear Factor Erythroid 2 Related Factor 2 pipeline targets constitutes close to 42 molecules. Out of which, approximately 36 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 5, 6, 1, 25, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 2 molecule.

Nuclear Factor Erythroid 2 Related Factor 2 overview

Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

For a complete picture of Nuclear Factor Erythroid 2 Related Factor 2’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.